Payment overview · 2025
General Payments
$900.19
43 reported records · 19 companies
Healthcare provider profile · identity verified
Alok Goyal, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · MILWAUKEE, WI · NPI 1487634036
Verified facts
What the public records show
CMS Open Payments records show Alok Goyal, M.D. received $900.19 in general payments during 2025 across 43 reported records.
ABBVIE INC. accounted for 16.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Ingrezza, Linzess, Mounjaro, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 252 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synthroid by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Zenpep by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 895 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 212 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 129 claims for Trulicity by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Ingrezza by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 895 claims for Eliquis by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Lantus by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SOLIQUA 100/33 as an associated drug or biological on 43 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Soliqua 100-33 by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $150.55 | 16.7% | 8 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $100.74 | 11.2% | 4 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $100.40 | 11.2% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $80.35 | 8.9% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $68.93 | 7.7% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $57.51 | 6.4% | 3 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $50.58 | 5.6% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $43.36 | 4.8% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $34.79 | 3.9% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $33.81 | 3.8% | 2 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $29.48 | 3.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $24.83 | 2.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $23.93 | 2.7% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $23.09 | 2.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $18.53 | 2.1% | 1 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $16.76 | 1.9% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $15.00 | 1.7% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $14.00 | 1.6% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $13.55 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $900.19 | 43 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $124.67 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $115.14 | 6 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $100.40 | 4 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $68.93 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $64.03 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $57.51 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $39.18 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $38.76 | 3 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $38.22 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $33.81 | 2 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $29.48 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $27.33 | 1 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $25.76 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $24.83 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $24.83 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $24.82 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $24.40 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $23.09 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $18.53 | 1 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $16.76 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.03 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.03 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $15.00 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $14.00 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $13.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 895 | exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 252 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
252 | 42 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
40 | 12 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
895 | 128 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
67 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
212 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
129 | 19 |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
895 | 128 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
64 | 21 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | SOLIQUA 100/33 open payments reported associated product |
CMS Open Payments — General Payments 43 supporting records · 15 recipient NPIs · example record 1233224976 |
Soliqua 100-33 · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1602 | 308 |
| Furosemide | Furosemide | 1182 | 229 |
| Gabapentin | Gabapentin | 1138 | 215 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1042 | 172 |
| Eliquis | Apixaban | 895 | 128 |
| Pantoprazole Sodium | Pantoprazole Sodium | 841 | 213 |
| Metoprolol Succinate | Metoprolol Succinate | 673 | 154 |
| Amlodipine Besylate | Amlodipine Besylate | 651 | 158 |
| Sertraline Hcl | Sertraline Hcl | 609 | 100 |
| Metoprolol Tartrate | Metoprolol Tartrate | 592 | 127 |
| Mirtazapine | Mirtazapine | 576 | 126 |
| Duloxetine Hcl | Duloxetine Hcl | 509 | 103 |
| Clopidogrel | Clopidogrel Bisulfate | 480 | 104 |
| Potassium Chloride | Potassium Chloride | 425 | 126 |
| Trazodone Hcl | Trazodone Hcl | 412 | 77 |
| Losartan Potassium | Losartan Potassium | 388 | 105 |
| Lisinopril | Lisinopril | 373 | 88 |
| Metformin Hcl | Metformin Hcl | 361 | 81 |
| Buspirone Hcl | Buspirone Hcl | 346 | 71 |
| Quetiapine Fumarate | Quetiapine Fumarate | 330 | 64 |
| Carvedilol | Carvedilol | 322 | 76 |
| Baclofen | Baclofen | 311 | 52 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 304 | 94 |
| Omeprazole | Omeprazole | 301 | 83 |
| Tamsulosin Hcl | Tamsulosin Hcl | 290 | 68 |
| Allopurinol | Allopurinol | 278 | 68 |
| Tizanidine Hcl | Tizanidine Hcl | 275 | 66 |
| Donepezil Hcl | Donepezil Hcl | 265 | 55 |
| Levetiracetam | Levetiracetam | 260 | 40 |
| Linzess | Linaclotide | 252 | 42 |
| Spironolactone | Spironolactone | 251 | 54 |
| Fluticasone Propionate | Fluticasone Propionate | 248 | 77 |
| Ropinirole Hcl | Ropinirole Hcl | 230 | 43 |
| Tramadol Hcl | Tramadol Hcl | 228 | 74 |
| Bumetanide | Bumetanide | 226 | 47 |
| Midodrine Hcl | Midodrine Hcl | 217 | 54 |
| Jardiance | Empagliflozin | 212 | 31 |
| Diclofenac Sodium | Diclofenac Sodium | 207 | 71 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 199 | 48 |
| Hydralazine Hcl | Hydralazine Hcl | 196 | 33 |
| Meloxicam | Meloxicam | 194 | 52 |
| Divalproex Sodium | Divalproex Sodium | 178 | 49 |
| Latanoprost | Latanoprost | 168 | 39 |
| Escitalopram Oxalate | Escitalopram Oxalate | 167 | 44 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 157 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 156 | 62 |
| Olanzapine | Olanzapine | 155 | 26 |
| Memantine Hcl | Memantine Hcl | 148 | 34 |
| Prednisone | Prednisone | 147 | 62 |
| Fluoxetine Hcl | Fluoxetine Hcl | 135 | 29 |
| Ondansetron Hcl | Ondansetron Hcl | 133 | 58 |
| Warfarin Sodium | Warfarin Sodium | 132 | 28 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 129 | 20 |
| Trulicity | Dulaglutide | 129 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 128 | 27 |
| Torsemide | Torsemide | 128 | 35 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 121 | 22 |
| Finasteride | Finasteride | 118 | 30 |
| Myrbetriq | Mirabegron | 111 | 22 |
| Pregabalin | Pregabalin | 109 | 35 |
| Alcohol Pads | Alcohol Antiseptic Pads | 108 | 15 |
| Alendronate Sodium | Alendronate Sodium | 108 | 24 |
| Metoclopramide Hcl | Metoclopramide Hcl | 108 | 20 |
| Celecoxib | Celecoxib | 107 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 105 | 26 |
| Aripiprazole | Aripiprazole | 104 | 17 |
| Simvastatin | Simvastatin | 104 | 29 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 103 | 46 |
| Xarelto | Rivaroxaban | 101 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 100 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 95 | 27 |
| Ezetimibe | Ezetimibe | 93 | 17 |
| Amiodarone Hcl | Amiodarone Hcl | 92 | 29 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 91 | 32 |
| Paroxetine Hcl | Paroxetine Hcl | 90 | 29 |
| Lidocaine | Lidocaine | 88 | 22 |
| Montelukast Sodium | Montelukast Sodium | 86 | 17 |
| Famotidine | Famotidine | 85 | 27 |
| Ozempic | Semaglutide | 82 | 21 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 81 | 23 |
| Glipizide | Glipizide | 80 | 16 |
| Humalog Kwikpen U-100 | Insulin Lispro | 80 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 79 | 23 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 79 | 15 |
| Cephalexin | Cephalexin | 76 | 47 |
| Entresto | Sacubitril/Valsartan | 75 | suppressed |
| Januvia | Sitagliptin Phosphate | 74 | 14 |
| Risperidone | Risperidone | 74 | 11 |
| Topiramate | Topiramate | 74 | 19 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 73 | 23 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 69 | 11 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 68 | 27 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 67 | 28 |
| Lactulose | Lactulose | 67 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 67 | 20 |
| Breo Ellipta | Fluticasone/Vilanterol | 65 | 13 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 64 | 21 |
| Bupropion Xl | Bupropion Hcl | 63 | 15 |
| Glimepiride | Glimepiride | 62 | 18 |
| Metformin Hcl Er | Metformin Hcl | 60 | 14 |
| Sevelamer Carbonate | Sevelamer Carbonate | 60 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 59 | suppressed |
| Ibuprofen | Ibuprofen | 59 | 17 |
| Nystatin | Nystatin | 59 | 33 |
| Atenolol | Atenolol | 57 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 55 | 12 |
| Acetic Acid | Acetic Acid | 53 | 11 |
| Albuterol Sulfate | Albuterol Sulfate | 53 | suppressed |
| Mupirocin | Mupirocin | 53 | 13 |
| Tradjenta | Linagliptin | 53 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 52 | 13 |
| Ondansetron Odt | Ondansetron | 52 | 23 |
| Doxycycline Hyclate | Doxycycline Hyclate | 51 | 35 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 51 | 18 |
| Venlafaxine Hcl | Venlafaxine Hcl | 51 | suppressed |
| Hydrocortisone | Hydrocortisone | 50 | 36 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 48 | 19 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 48 | 38 |
| Doxazosin Mesylate | Doxazosin Mesylate | 47 | 18 |
| Sucralfate | Sucralfate | 47 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 46 | 11 |
| Diltiazem 24hr Er | Diltiazem Hcl | 46 | suppressed |
| Nystop | Nystatin | 46 | 25 |
| Lamotrigine | Lamotrigine | 45 | 15 |
| Oxcarbazepine | Oxcarbazepine | 45 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 45 | 29 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 45 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 44 | 12 |
| Meclizine Hcl | Meclizine Hcl | 42 | 19 |
| Symbicort | Budesonide/Formoterol Fumarate | 40 | 12 |
| Nyamyc | Nystatin | 39 | 22 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 38 | 27 |
| Humalog | Insulin Lispro | 38 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 38 | 13 |
| Lubiprostone | Lubiprostone | 35 | suppressed |
| Methotrexate | Methotrexate Sodium | 35 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 35 | 33 |
| Verapamil Er | Verapamil Hcl | 35 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 34 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 34 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 19 |
| Bupropion Hcl | Bupropion Hcl | 33 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 33 | suppressed |
| Amoxicillin | Amoxicillin | 32 | 20 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 32 | suppressed |
| Levemir | Insulin Detemir | 32 | suppressed |
| Ranolazine Er | Ranolazine | 32 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 32 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 31 | suppressed |
| Ketoconazole | Ketoconazole | 31 | 16 |
| Lovastatin | Lovastatin | 31 | suppressed |
| Movantik | Naloxegol Oxalate | 31 | suppressed |
| Calcium Acetate | Calcium Acetate | 30 | suppressed |
| Estradiol | Estradiol | 30 | 13 |
| Diclofenac Potassium | Diclofenac Potassium | 29 | suppressed |
| Metolazone | Metolazone | 29 | 14 |
| Amantadine | Amantadine Hcl | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Calcitriol | Calcitriol | 28 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 28 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 28 | suppressed |
| Scopolamine | Scopolamine | 28 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 28 | suppressed |
| Clonidine | Clonidine | 27 | suppressed |
| Fluconazole | Fluconazole | 27 | 24 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 27 | suppressed |
| Levemir Flexpen | Insulin Detemir | 27 | suppressed |
| Rybelsus | Semaglutide | 27 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 27 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 27 | suppressed |
| Acyclovir | Acyclovir | 26 | 12 |
| Digoxin | Digoxin | 26 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 26 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 26 | 13 |
| Primidone | Primidone | 26 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 25 | 11 |
| Loperamide | Loperamide Hcl | 25 | 16 |
| Ventolin Hfa | Albuterol Sulfate | 25 | 15 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 24 | suppressed |
| Cyclosporine | Cyclosporine | 24 | suppressed |
| Dantrolene Sodium | Dantrolene Sodium | 24 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 23 | suppressed |
| Easy Comfort Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 23 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 23 | suppressed |
| Insulin Lispro | Insulin Lispro | 23 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 22 | suppressed |
| Novolog Flexpen | Insulin Aspart | 22 | 11 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 22 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 21 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 21 | 11 |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 21 | suppressed |
| Trexall | Methotrexate Sodium | 21 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 20 | suppressed |
| Carbamazepine | Carbamazepine | 20 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 20 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 20 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 16 |
| Nitroglycerin | Nitroglycerin | 20 | 16 |
| Pentoxifylline | Pentoxifylline | 20 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 19 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 19 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 19 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 19 | suppressed |
| Methimazole | Methimazole | 19 | suppressed |
| Methocarbamol | Methocarbamol | 19 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 18 | suppressed |
| Dexamethasone | Dexamethasone | 18 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 18 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 18 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 18 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 17 | 11 |
| Ipratropium Bromide | Ipratropium Bromide | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 11 |
| Memantine Hcl Er | Memantine Hcl | 17 | suppressed |
| Mounjaro | Tirzepatide | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Paliperidone Er | Paliperidone | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Ursodiol | Ursodiol | 17 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 17 | 14 |
| Ammonium Lactate | Ammonium Lactate | 16 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 16 | 14 |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Ingrezza | Valbenazine Tosylate | 16 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 16 | suppressed |
| Olanzapine Odt | Olanzapine | 16 | suppressed |
| Restasis | Cyclosporine | 16 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 16 | suppressed |
| Admelog | Insulin Lispro | 15 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Azithromycin | Azithromycin | 15 | 12 |
| Ceftriaxone | Ceftriaxone Sodium | 15 | 11 |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Indomethacin | Indomethacin | 15 | suppressed |
| Klayesta | Nystatin | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 15 | suppressed |
| Timolol Maleate | Timolol Maleate | 15 | suppressed |
| Lorazepam | Lorazepam | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 14 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 14 | suppressed |
| Acetylcysteine | Acetylcysteine | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 13 | suppressed |
| Carbamazepine Er | Carbamazepine | 13 | suppressed |
| Lyvispah | Baclofen | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 13 | suppressed |
| Repaglinide | Repaglinide | 13 | suppressed |
| Steglatro | Ertugliflozin Pidolate | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 13 | suppressed |
| Alprazolam | Alprazolam | 12 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 12 | suppressed |
| Corlanor | Ivabradine Hcl | 12 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Probenecid-Colchicine | Probenecid/Colchicine | 12 | suppressed |
| Rytary | Carbidopa/Levodopa | 12 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 12 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 11 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 11 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
| Mirabegron Er | Mirabegron | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $900.19 · 43 records | ABBVIE INC. | AREXVY, AUSTEDO XR, Arikayce, Auvelity, BREZTRI, CAPLYTA, CREON, ELIQUIS, GEMTESA, INGREZZA, KISUNLA, Kerendia, LINZESS, MOUNJARO, QULIPTA, REXULTI, SHINGRIX, SUBLOCADE, TZIELD, The Cologuard Plus Collection Kit, UBRELVY, VOWST, VRAYLAR, ZENPEP, ZEPBOUND | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error